https://www.live-feeds.com/feed/f-d-a-approves-drug-poised-to-transform-care-for-pancreatic-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/f-d-a-approves-drug-poised-to-transform-care-for-pancreatic-cancerhttps://www.live-feeds.com/feed/f-d-a-approves-drug-poised-to-transform-care-for-pancreatic-cancer#u51068Sat, 29 Aug 2026 00:16:20 +0000The FDA approved daraxonrasib on Wednesday, an oral targeted therapy developed by Revolution Medicines for pancreatic cancer. Clinical trial data suggests the pill can double survival time for patients. This approval targets a disease known for high mortality rates and limited treatment options, particularly for those with metastatic cancer. Experts predict the drug will transform the management of one of the deadliest forms of cancer by providing a new alternative to traditional difficult treatments.Why it mattersPancreatic cancer has historically offered patients few options and short surviv https://www.live-feeds.com/feed/f-d-a-approves-drug-poised-to-transform-care-for-pancreatic-cancerhttps://www.live-feeds.com/feed/f-d-a-approves-drug-poised-to-transform-care-for-pancreatic-cancer#u49632Thu, 27 Aug 2026 06:05:14 +0000The FDA granted expedited approval to daraxonrasib, an oral targeted therapy developed by Revolution Medicines for pancreatic cancer. Clinical trial data indicated the drug could double survival time for patients. The approval follows results that experts describe as a substantial breakthrough for a disease typically characterized by high mortality rates. Former Nebraska Senator Ben Sasse previously shared his personal experience using the medication earlier this year.Why it mattersPancreatic cancer is known for being deadly with limited treatment options. This new therapy uses a targeted appr